Structure of plasma and tissue kallikreins

Summary

The kallikrein kinin system (KKS) consists of serine proteases involved in the production of peptides called kinins, principally bradykinin and Lys-bradykinin (kallidin). The KKS contributes to a variety of physiological processes including inflammation, blood pressure control and coagulation. Here we review the protein structural data available for these serine proteases and examine the molecular mechanisms of zymogen activation and substrate recognition focusing on plasma kallikrein (PK) and tissue kallikrein (KLK1) cleavage of kininogens. PK circulates as a zymogen bound to high-molecular-weight kininogen (HK). PK is activated by coagulation factor XIIa and then cleaves HK to generate bradykinin and factor XII to generate further XIIa. A structure has been described for the activated PK protease domain in complex with the inhibitor benzamidine. Kallikrein-related peptidases (KLKs) have a distinct domain structure and exist as a family of 15 genes which are differentially expressed in many tissues and the central nervous system. They cleave a wide variety of substrates including low-molecular-weight kininogen (LK) and matrix proteins. Crystal structures are available for KLK1, 3, 4, 5, 6 and 7 activated protease domains typically in complex with S1 pocket inhibitors. A substrate mimetic complex is described for KLK3 which provides insight into substrate recognition. A zymogen crystal structure determined for KLK6 reveals a closed S1 pocket and a novel mechanism of zymogen activation. Overall these structures have proved highly informative in understanding the molecular mechanisms of the KKS and provide templates to design inhibitors for treatment of a variety of diseases.

Keywords

Plasma kallikrein - tissue kallikrein - kininogen - zymogen activation - substrate recognition

• References

• 1 Clements JA, Willemsen NM, Myers SA. et al. The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Lab Sci 2004; 41: 265-312.
• 2 Yousef GM, Obiezu CV, Luo LY. et al. Human tissue kallikreins: from gene structure to function and clinical applications. Adv Clin Chem 2005; 39: 11-79.
• 3 Sainz IM, Pixley RA, Colman RW. Fifty years of research on the plasma kallikrein-kinin system: from protein structure and function to cell biology and in-vivo pathophysiology. Thromb Haemost 2007; 98: 77-83.
• 4 Kaplan AP, Joseph K, Shibayama Y. et al. Bradykinin formation. Plasma and tissue pathways and cellular interactions. Clin Rev Allergy Immunol 1998; 16: 403-429.
• 5 Costa-Neto CM, Dillenburg-Pilla P, Heinrich TA. et al. Participation of kallikrein-kinin system in different pathologies. Int Immunopharmacol 2008; 08: 135-142.
• 6 Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 1997; 90: 3819-3843.
• 7 Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev 2001; 22: 184-204.
• 8 LeBeau AM, Craik Charles S. Molecular Recognition Properties of Kallikrein-related Peptidases on Synthetic and Endogenous Substrates. Kallikrein Rel Peptid 2012; 2012: 117-140.
• 9 Maas C, Oschatz C, Renne T. The plasma contact system 2.0. Semin Thromb Hemost 2011; 37: 375-381.
• 10 Revenko AS, Gao D, Crosby JR. et al. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood 2011; 118: 5302-5311.
• 11 Kleinschnitz C, Stoll G, Bendszus M. et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006; 203: 513-518.
• 12 Merkulov S, Zhang WM, Komar AA. et al. Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. Blood 2008; 111: 1274-1281.
• 13 Kaplan AP, Joseph K, Silverberg M. Pathways for bradykinin formation and inflammatory disease. J Allergy Clin Immunol 2002; 109: 195-209.
• 14 Cichon S, Martin L, Hennies HC. et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006; 79: 1098-1104.
• 15 Zhao Y, Qiu Q, Mahdi F. et al. Assembly and activation of HK-PK complex on endothelial cells results in bradykinin liberation and NO formation. Am J Physiol Heart Circ Physiol 2001; 280: H1821-H1829.
• 16 Yousef GM, Diamandis EP. Human tissue kallikreins: a new enzymatic cascade pathway?. Biol Chem 2002; 383: 1045-1057.
• 17 Li HX, Hwang BY, Laxmikanthan G. et al. Substrate specificity of human kallikreins 1 and 6 determined by phage display. Protein Sci 2008; 17: 664-672.
• 18 Hooley E, McEwan PA, Emsley J. Molecular modeling of the prekallikrein structure provides insights into high-molecular-weight kininogen binding and zymogen activation. J Thromb Haemost 2007; 05: 2461-2466.
• 19 Laxmikanthan G, Blaber SI, Bernett MJ. et al. 1.70 A X-ray structure of human apo kallikrein 1: structural changes upon peptide inhibitor/substrate binding. Proteins 2005; 58: 802-814.
• 20 Fiedler F, Leysath G. Substrate specificity of porcine pancreatic kallikrein. Adv Exp Med Biol 1979; 120A: 261-271.
• 21 Pimenta DC, Juliano MA, Juliano L. Hydrolysis of somatostatin by human tissue kallikrein after the amino acid pair phe-Phe. Biochem J 1997; 327: 27-30.
• 22 Malm J, Hellman J, Hogg P. et al. Enzymatic action of prostate-specific antigen (PSA or hK3): substrate specificity and regulation by Zn(2+), a tight-binding inhibitor. Prostate 2000; 45: 132-139.
• 23 Bailey TL, Elkan C. Fitting a mixture model by expectation maximization to discover motifs in biopolymers. Proc Int Conf Intell Syst Mol Biol 1994; 02: 28-36.
• 24 Lima AR, Alves FM, Angelo PF. et al. S(1)′ and S(2)′ subsite specificities of human plasma kallikrein and tissue kallikrein 1 for the hydrolysis of peptides derived from the bradykinin domain of human kininogen. Biol Chem 2008; 389: 1487-1494.
• 25 Chagas JR, Portaro FC, Hirata IY. et al. Determinants of the unusual cleavage specificity of lysyl-bradykinin-releasing kallikreins. Biochem J 1995; 306: 63-69.
• 26 Goettig P, Magdolen V, Brandstetter H. Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs). Biochimie 2010; 92: 1546-1567.
• 27 Chen Z, Bode W. Refined 2.5 A X-ray crystal structure of the complex formed by porcine kallikrein A and the bovine pancreatic trypsin inhibitor. Crystallization, Patterson search, structure determination, Refinement, structure and comparison with its components and with the bovine trypsin-pancreatic trypsin inhibitor complex. J Mol Biol 1983; 164: 283-311.
• 28 Mittl PR, Di Marco S, Fendrich G. et al. A new structural class of serine protease inhibitors revealed by the structure of the hirustasin-kallikrein complex. Structure 1997; 05: 253-264.
• 29 Chen VC, Chao L, Chao J. Roles of the P1, P2, and P3 residues in determining inhibitory specificity of kallistatin toward human tissue kallikrein. J Biol Chem 2000; 275: 38457-38466.
• 30 Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004; 60: 2126-2132.
• 31 Khan AR, James MN. Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes. Protein Sci 1998; 07: 815-836.
• 32 Huntington JA. Slow thrombin is zymogen-like. J Thromb Haemost 2009; 07 (Suppl. 01) 159-164.
• 33 Bode W, Huber R. Induction of the bovine trypsinogen-trypsin transition by peptides sequentially similar to the N-terminus of trypsin. FEBS Lett 1976; 68: 231-236.
• 34 Tang J, Yu CL, Williams SR. et al. Expression, crystallization, and three-dimensional structure of the catalytic domain of human plasma kallikrein. J Biol Chem 2005; 280: 41077-41089.
• 35 Renne T, Sugiyama A, Gailani D. et al. Fine mapping of the H-kininogen binding site in plasma prekallikrein apple domain 2. Int Immunopharmacol 2002; 02: 1867-1873.
• 36 Herwald H, Jahnen-Dechent W, Alla SA. et al. Mapping of the high molecular weight kininogen binding site of prekallikrein. Evidence for a discontinuous epitope formed by distinct segments of the prekallikrein heavy chain. J Biol Chem 1993; 268: 14527-14535.
• 37 Renne T, Dedio J, Meijers JC. et al. Mapping of the discontinuous H-kininogen binding site of plasma prekallikrein. Evidence for a critical role of apple domain-2. J Biol Chem 1999; 274: 25777-25784.
• 38 Tait JF, Fujikawa K. Primary structure requirements for the binding of human high molecular weight kininogen to plasma prekallikrein and factor XI. J Biol Chem 1987; 262: 11651-11656.
• 39 Vogel R, Kaufmann J, Chung DW. et al. Mapping of the prekallikrein-binding site of human H-kininogen by ligand screening of lambda gt11 expression libraries. Mimicking of the predicted binding site by anti-idiotypic antibodies. J Biol Chem 1990; 265: 12494-12502.
• 40 Wuepper KD, Cochrane CG. Plasma prekallikrein: isolation, characterization, and mechanism of activation. J Exp Med 1972; 135: 1-20.
• 41 Kaplan AP, Silverberg M. The coagulation-kinin pathway of human plasma. Blood 1987; 70: 1-15.
• 42 Papagrigoriou E, McEwan PA, Walsh PN. et al. Crystal structure of the factor XI zymogen reveals a pathway for transactivation. Nat Struct Mol Biol 2006; 13: 557-558.
• 43 Weisel JW, Nagaswami C, Woodhead JL. et al. The shape of high molecular weight kininogen. Organization into structural domains, changes with activation, and interactions with prekallikrein, as determined by electron microscopy. J Biol Chem 1994; 269: 10100-10106.
• 44 Shariat-Madar Z, Mahdi F, Schmaier AH. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem 2002; 277: 17962-17969.
• 45 Rabey FM, Gadepalli RS, Diano S. et al. Influence of a Novel Inhibitor (UM8190) of Prolylcarboxypeptidase (PRCP) on Appetite and Thrombosis. Curr Med Chem 2012; 19: 4194-4206.
• 46 Emsley J, McEwan PA, Gailani D. Structure and function of factor XI. Blood 2010; 115: 2569-2577.
• 47 Wolberg AS, Morris DP, Stafford DW. Factor IX activation by factor XIa proceeds without release of a free intermediate. Biochemistry 1997; 36: 4074-4079.
• 48 Samuel D, Cheng H, Riley PW. et al. Solution structure of the A4 domain of factor XI sheds light on the mechanism of zymogen activation. Proc Natl Acad Sci USA 2007; 104: 15693-15698.
• 49 Langhauser F, Gob E, Kraft P. et al. Kininogen deficiency protects from ischemic neurodegeneration in mice by reducing thrombosis, blood-brain barrier damage, and inflammation. Blood 2012; 120: 4082-4092.
• 50 Houlihan LM, Davies G, Tenesa A. et al. Common variants of large effect in F12, KNG1, and HRG are associated with activated partial thromboplastin time. Am J Hum Genet 2010; 86: 626-631.
• 51 Morange PE, Oudot-Mellakh T, Cohen W. et al. KNG1 Ile581Thr and susceptibility to venous thrombosis. Blood 2011; 117: 3692-3694.
• 52 Sotiropoulou G, Pampalakis G. Targeting the kallikrein-related peptidases for drug development. Trends Pharmacol Sci 2012; 33: 623-634.
• 53 Muller F, Gailani D, Renne T. Factor XI and XII as antithrombotic targets. Curr Opin Hematol 2011; 18: 349-355.